(Q36397924)

English

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US i

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US i (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

0 references

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Martin S. Tallman

18

object named as

Martin S Tallman

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

19

object named as

John C Byrd

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Frederick R. Appelbaum

15

object named as

Frederick R Appelbaum

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

Richard A. Larson

16

object named as

Richard A Larson

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Elisabeth Paietta

10

object named as

Elisabeth M Paietta

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Diane F. Jelinek

12

object named as

Diane F Jelinek

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

David M Lucas

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Amy S Ruppert

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gerard Lozanski

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gordon W Dewald

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Arletta Lozanski

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Rainer Claus

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Christoph Plass

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ian W Flinn

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Donna S Neuberg

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

John M Bennett

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

John G Gribben

13

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Mohamad A Hussein

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dennis F Moore

17

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Michael R Grever

20

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

publication date

27 February 2015

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

56

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

3031-3037

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

30 September 2017

CLL and NHL: the end of chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688910

21 September 2018

Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25721902

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428194.2015.1023800

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36397924&oldid=1989876136"